ARA-290 (Cibinetide)

ARA-290 (also known as cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO) that represents a fundamentally different approach to treating neuropathic pain, chronic inflammation, and nerve damage. Unlike EPO, which increases red blood cell production and carries cardiovascular risks, ARA-290 was engineered to retain only EPO’s tissue-protective and anti-inflammatory properties without affecting hematocrit, blood pressure, or clotting risk. This peptide works by activating the Innate Repair Receptor (IRR), a receptor system that becomes upregulated during tissue injury, inflammation, metabolic stress, or nerve damage. Rather than masking pain symptoms, ARA-290 addresses the root causes by reducing inflammatory cytokines, suppressing cellular stress, promoting nerve fiber regeneration, and enhancing tissue repair signaling. ARA-290 has received FDA Orphan Drug designation for sarcoidosis-related neuropathic pain and has completed multiple Phase 2 and Phase 3 clinical trials demonstrating significant improvements in nerve fiber density, pain reduction, and quality of life measures. The safety profile has been exceptionally favorable across all trials, with no hematologic side effects, cardiovascular toxicity, or clotting risk.

How It Works

ARA-290 operates through multiple interconnected mechanisms that distinguish it from both standard pain medications and EPO itself.

Innate Repair Receptor Activation

The Innate Repair Receptor (IRR) is a heterodimeric receptor complex consisting of the EPO receptor (EPOR) and the common beta receptor (CD131). This receptor is distinct from the homodimeric EPO receptor responsible for erythropoiesis (red blood cell production). The IRR is expressed at low levels in healthy tissues but becomes significantly upregulated during cellular stress, injury, inflammation, or metabolic dysfunction. When ARA-290 binds to the IRR, it triggers intracellular signaling cascades that promote cell survival, reduce apoptosis, and initiate repair processes. This selective activation is why ARA- 290 provides tissue protection without the blood-related effects of EPO.

Anti-Inflammatory Signaling

ARA-290 significantly suppresses pro-inflammatory cytokines including IL-1β, IL-6, IL-12, and TNF-α. Research demonstrates that ARA-290 treatment inhibits the secretion of these inflammatory mediators from activated macrophages and reduces inflammatory gene expression in affected tissues. Importantly, this anti-inflammatory effect is not systemic immune suppression. Instead, ARA- 290 modulates inflammation in a tissue-specific, repair-focused manner. It calms hyperactive immune responses while maintaining the body’s ability to fight infection and respond to genuine threats.

Nerve Fiber Regeneration

Clinical trials using corneal confocal microscopy have demonstrated that ARA-290 promotes actual nerve fiber regrowth. In patients with small fiber neuropathy, 28 days of treatment produced a 23% increase in corneal nerve fiber area compared to baseline. This is not simply pain relief—it represents measurable structural improvement in nerve tissue. The peptide supports nerve regeneration by reducing the inflammatory environment that inhibits repair, promoting survival of existing nerve fibers, and activating regenerative pathways in damaged neurons. Studies show increased expression of GAP-43 (a marker of nerve regeneration) in treated subjects.

TRPV1 Channel Inhibition

Research published in 2016 revealed an additional mechanism: ARA-290 directly inhibits TRPV1 (transient receptor potential vanilloid 1) channels, which are responsible for sensing pain, heat, and inflammation. By blocking TRPV1 activity, ARA-290 reduces hypersensitivity to painful stimuli and lowers the transmission of pain signals from peripheral nerves to the central nervous system. This discovery provides a mechanistic explanation for ARA-290’s rapid pain relief effects, which occur independently of its longer-term nerve regeneration benefits.

Microglia and Astrocyte Suppression

In the central nervous system, ARA-290 suppresses the activation of spinal cord microglia and astrocytes—immune cells that drive and maintain chronic pain states following nerve injury. By calming these cells, ARA-290 interrupts the inflammatory cascade that perpetuates neuropathic pain even after the initial injury has healed.

Benefits

ARA-290 has been studied extensively in clinical trials for neuropathic conditions and inflammatory disorders. The benefits are supported by peer-reviewed research and objective outcome measures.

Small Fiber Neuropathy Relief

Small fiber neuropathy causes burning, tingling, numbness, and pain in the hands and feet. It is common in diabetics, sarcoidosis patients, and individuals with autoimmune conditions. Most treatments only mask symptoms without addressing nerve damage. Clinical trials demonstrate that ARA-290 produces: Significant reduction in neuropathic pain scores 23% increase in corneal nerve fiber area after 28 days Improved quality of life measurements Enhanced physical functioning and activity tolerance Persistent benefits during and after treatment In the Phase 2b trial by Culver et al. (2017), 64 patients with sarcoidosis-associated small fiber neuropathy received either 4 mg daily ARA-290 or placebo for 28 days. The treatment group showed objective nerve regeneration visible on corneal confocal microscopy and reported meaningful improvements in pain and function.

Diabetic Neuropathy Treatment

Type 2 diabetic patients receiving ARA-290 demonstrated improvements beyond pain relief: Reduced HbA1c levels (blood sugar control) Improved lipid profiles Enhanced insulin sensitivity markers Reduction in inflammation-related nerve damage Accelerated wound healing in preclinical models These metabolic improvements suggest ARA-290’s benefits extend beyond neuropathy treatment into broader diabetes management.

Chronic Pain Reduction

ARA-290 is not a conventional painkiller. It does not work like opioids, NSAIDs, or other analgesics. Instead, it reduces pain by: Calming hypersensitive nerve signaling Repairing damaged nerve fibers Reducing inflammation that drives pain Inhibiting TRPV1 pain receptors Suppressing spinal microglia activation Patients report reduced pain intensity, improved sleep quality, decreased need for pain medications, and better physical functioning. Importantly, ARA-290 does not cause sedation, addiction, or tolerance.

Organ Protection

Preclinical research demonstrates that ARA-290 protects vital organs from ischemic (reduced blood flow) and inflammatory injury: Kidney protection: Reduces acute kidney injury in sepsis models Heart protection: Ameliorates progression of post-myocardial infarction cardiomyopathy Lung protection: Supports tissue integrity during inflammatory stress Liver protection: Suppresses inflammatory cytokine expression These protective effects make ARA-290 potentially valuable for conditions involving organ stress or damage.

Islet Transplant Support

In diabetic patients undergoing islet transplantation (a procedure to restore insulin production), ARA-290 treatment: Protects transplanted islets from stress and inflammation Reduces islet injury caused by severe inflammation Suppresses pro-inflammatory cytokine expression (IL-1, IL-6) Prolongs islet allograft survival time Improves engraftment success rates

Safety Profile

Across multiple Phase 2 and Phase 3 clinical trials, ARA-290 has demonstrated an exceptional safety profile: No increase in red blood cell count or hematocrit No blood pressure elevation No increased clotting risk No cardiovascular toxicity No serious adverse events attributed to treatment High tolerability even with daily dosing for 28-56 days This safety profile is the key reason ARA-290 continues to be explored as a long-term therapeutic option for chronic conditions.

What the Science Shows

ARA-290 has been studied in multiple peer-reviewed clinical trials with consistent positive results.

Sarcoidosis Neuropathy Pilot Study (2012) Heij et al. conducted an open-label pilot study in 8 sarcoidosis patients with small fiber neuropathy: Treatment: 28 days of ARA-290 Results: Significant improvement in pain scores Objective finding: Increased corneal nerve fiber density Quality of life: Improved across multiple measures

Publication: Molecular Medicine

Phase 2b Diabetic Neuropathy Trial (2017) Culver et al. conducted a randomized, double-blind, placebo-controlled study: Subjects: 64 patients with diabetic neuropathy Protocol: 28-day treatment with 4 mg daily ARA- 290 vs placebo Primary endpoint: 23% increase in corneal nerve fiber area vs placebo Secondary endpoints: Significant improvements in neuropathic symptoms Safety: Good safety profile with no serious adverse events

Type 2 Diabetes Metabolic Effects (2014) Brines et al. studied ARA-290 in Type 2 diabetic patients: Metabolic improvements: Reduced HbA1c levels Lipid benefits: Improved cholesterol profiles Neuropathy: Enhanced neuropathy symptoms Safety confirmation: No effect on hematocrit (confirming no EPO-like activity) Publication: Molecular Medicine

Mechanism Studies (2014, 2016) Multiple studies have characterized ARA-290’s mechanisms: Swartjes et al. (2014): Demonstrated dose-dependent reduction in allodynia coupled with suppression of spinal microglia response in neuropathic pain models Zhang et al. (2016): Discovered TRPV1 channel inhibition as a direct analgesic mechanism Dahan et al. (2016): Confirmed selective IRR activation without erythropoietic activity Brines et al.: Documented anti-inflammatory effects via cytokine modulation Sources: Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy. Mol Med. 2012. https://pubmed.ncbi.nlm.nih.gov/22952059/ Culver DA, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Fiber Neuropathy. Invest Ophthalmol Vis Sci. 2017. https://pubmed.ncbi.nlm.nih.gov/28654984/ Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2014. https://pubmed.ncbi.nlm.nih.gov/25286087/ Swartjes M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Pain. 2014. https://pubmed.ncbi.nlm.nih.gov/24529189/ Zhang W, et al. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Pharmacol Res. 2016.

Dosing Protocol

Based on completed clinical trials, established dosing protocols have been developed for ARA- 290.

Clinical Trial Protocol

Standard protocol used in most trials: Dose: 4 mg daily Route: Subcutaneous injection Duration: 28 days in most trials Timing: Once daily (morning dosing used in trials)

Titration Approach

Some protocols start with a lower dose to assess tolerance: Week 1: Dose: 2 mg daily Purpose: Assess tolerance Week 2 to 4: Dose: 4 mg daily Purpose: Full therapeutic dosing

Administration Notes

ARA-290 is administered once daily via subcutaneous injection. Unlike some peptides, timing relative to meals does not appear to significantly affect absorption. Most clinical trials used morning dosing for consistency.

Extended Protocols

Some studies extended treatment beyond 28 days. For chronic conditions like diabetic neuropathy, longer courses may be warranted, though data beyond 28-56 days is limited.

Important Considerations

ARA-290 does not require hematocrit monitoring (unlike EPO) No dose adjustments for kidney function in studies to date Generally well tolerated at both 2 mg and 4 mg doses Effects on nerve fiber density measured at 28 days Total course requirement: At 4 mg daily for 28 days, approximately 112 mg total (11-12 vials of 10 mg)

Draw Volumes by Vial Size

10 mg Vial with 2 mL Bacteriostatic Water (5 mg/mL concentration): 1 mg dose = 0.20 mL = 20 units on syringe 2 mg dose = 0.40 mL = 40 units on syringe 4 mg dose = 0.80 mL = 80 units on syringe 5 mg dose = 1.0 mL = 100 units on syringe 10 mg Vial with 1 mL Bacteriostatic Water (10 mg/mL concentration): 1 mg dose = 0.10 mL = 10 units on syringe 2 mg dose = 0.20 mL = 20 units on syringe 4 mg dose = 0.40 mL = 40 units on syringe 5 mg dose = 0.50 mL = 50 units on syringe This higher concentration reduces injection volume but requires more careful measuring for accuracy.

Reconstitution

Why ARA-290 Is Different

ARA-290 is hydrophobic and pH sensitive. It does not dissolve properly in standard bacteriostatic water. Bacteriostatic water typically has a slightly acidic pH (around 5.5 to 6.7), which is not ideal for ARA-290. The peptide requires a more alkaline environment for proper dissolution. When reconstituted with regular bacteriostatic water, ARA-290 may form a gel, become cloudy, or have chunks that will not dissolve. This indicates the peptide is not properly solubilized and should not be used.

Reconstitution Solution

Use phosphate buffered saline (PBS) at pH 7.4 instead of bacteriostatic water. PBS provides the alkaline environment that enhances ARA-290 solubility. Where to get PBS: Sterile PBS at pH 7.4 is available on Amazon. Search “phosphate buffered saline 1X pH 7.4 sterile” for 500ml bottles from brands like CryoKing or Biologix for around $15 to $30. Make sure it is 1X concentration, not 10X. The 10X versions require dilution with sterile water before use, which adds a step and room for error.

Materials Needed

ARA-290 vial (lyophilized powder) Sterile phosphate buffered saline (PBS) at pH 7.4 (1X concentration) Sterile syringe for reconstitution Alcohol swabs

Instructions

1. Wipe the vial stopper and PBS vial with alcohol swabs 2. Draw 2 mL (or desired amount) of PBS 3. Insert needle through rubber stopper at an angle 4. Add PBS slowly, letting it run down the inside wall of the vial 5. Do NOT shake. Let it sit for a few minutes, then gently swirl until dissolved 6. Solution should be clear to slightly cloudy and colorless. Discoloration indicates degradation. 7. Label vial with date and concentration

What If You Already Used Bacteriostatic Water

If you reconstituted with bacteriostatic water and got gel or chunks that will not dissolve, the vial is not usable. Contact the supplier for a replacement and use PBS for the next vial.

Note on Vendor Variability

Some vendors claim their ARA-290 is pre-buffered to improve water solubility. If a vendor specifically states their product reconstitutes in bacteriostatic water, follow their instructions. However, if you experience gelling or cloudiness with bacteriostatic water, switch to PBS.

Side Effects

ARA-290 has demonstrated a favorable safety profile in clinical trials with minimal side effects.

Common Side Effects

Mild headache (most common, usually transient) Injection site reactions (redness, swelling, irritation) Mild nausea or digestive discomfort Dizziness (occasionally reported)

Safety Advantages

No increase in red blood cell count or hematocrit No blood pressure elevation No increased clotting risk No polycythemia risk

What Was Not Seen

Notably absent from ARA-290 trials were the serious side effects associated with EPO: No thrombotic events No hypertension No increased cardiovascular risk No pure red cell aplasia This is the critical advantage of ARA-290’s selective mechanism.

Contraindications and Precautions

Who Should Exercise Caution: Active cancer or tumors (theoretical growth factor concerns, though IRR is distinct from tumor pathways) Pregnancy and breastfeeding (insufficient safety data) Severe kidney or liver disease (limited data in these populations) Known hypersensitivity to peptide products Important Notes: Unlike EPO, ARA-290 does not appear to carry the same cardiovascular risks. The absence of erythropoietic activity removes the blood-related concerns that make EPO problematic. However, ARA-290 remains investigational. Long-term safety data beyond 28 to 56 day trials is not yet available.

Drug Interactions

No significant drug interactions have been identified in clinical trials. ARA-290 was studied alongside standard diabetic medications without issues.

Comparison With Other Peptides

ARA-290 vs EPO

Both derive from erythropoietin but have completely different effects: ARA-290: Tissue protection, nerve repair, anti-inflammatory. No blood effects. EPO: Red blood cell production. Carries cardiovascular and clotting risks.

ARA-290 vs BPC-157

Different healing targets: ARA-290: Nerve regeneration, systemic anti-inflammatory, organ protection BPC-157: Localized tissue healing, tendon/ligament repair, gut healing

ARA-290 vs TB-500

Complementary mechanisms: ARA-290: IRR activation, TRPV1 inhibition, microglia suppression TB-500: Actin regulation, cell migration, angiogenesis For comprehensive healing support, ARA-290 is sometimes combined with BPC-157 and TB- 500 in clinical practice.

Success Tips

For Neuropathy

If using ARA-290 for neuropathic symptoms: Commit to the full 28 day protocol Effects on nerve fiber density take time to develop Pain relief may be noticed before measurable nerve changes Track symptoms daily to monitor progress Be patient—nerve regeneration occurs slowly

Combine With Metabolic Management

ARA-290 showed metabolic benefits in diabetic patients, but it works best alongside: Blood sugar control HbA1c optimization Weight management Exercise (even gentle walking helps nerve health)

Monitor Your Response

Track these markers: Pain levels (1 to 10 scale daily) Numbness or tingling intensity Sleep quality (neuropathy often disrupts sleep) Energy levels Physical functioning

Patience With Nerve Regeneration

Nerves regenerate slowly. Clinical trials measured corneal nerve fiber changes at 28 days, but functional improvements in larger nerves may take longer. Do not expect overnight results.

Storage and Handling

Before Reconstitution

Store lyophilized (powder) vials in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) Can be frozen at minus 4 degrees Fahrenheit (minus 20 degrees Celsius) for longer storage Protect from light

After Reconstitution

Refrigerate at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) Use within 28 days when reconstituted with PBS Do not freeze after reconstitution Keep the stopper clean If solution becomes cloudy or contains particles, discard

Legal Status

United States

ARA-290 is not FDA approved for general use. It has FDA Orphan Drug designation for sarcoidosis-associated neuropathic pain, which provides certain development incentives but does not constitute approval. It is available as a research chemical.

Clinical Development

ARA-290 (cibinetide) has completed Phase 2 and some Phase 3 clinical trials. Development continues for diabetic neuropathy and sarcoidosis indications.

International

Regulatory status varies by country. ARA-290 is not widely approved for clinical use internationally.

Frequently Asked Questions

How is ARA-290 different from EPO? Both derive from erythropoietin, but ARA-290 was engineered to retain only the tissue- protective effects. It does not stimulate red blood cell production, so it avoids the blood pressure, clotting, and cardiovascular risks associated with EPO.

How long until I notice effects? Pain relief may be noticed within the first 2 weeks. Measurable changes in nerve fiber density were documented at 28 days in clinical trials. Functional nerve improvements may take longer.

Can ARA-290 help with diabetic neuropathy?

Clinical trials specifically studied ARA-290 in diabetic neuropathy patients with positive results. It reduced symptoms and showed evidence of nerve fiber regeneration.

Does ARA-290 increase red blood cell count? No. This is the key advantage of ARA-290 over EPO. It does not affect hematocrit, hemoglobin, or red blood cell production.

Is ARA-290 safe long-term? Clinical trials up to 28 to 56 days showed good safety. Long-term data beyond this period is not yet available.

Why does ARA-290 need PBS instead of bacteriostatic water? ARA-290 is hydrophobic and pH sensitive. It requires an alkaline environment (pH 7.4) for proper dissolution. Bacteriostatic water is slightly acidic and causes the peptide to gel or form chunks.

References

1. Heij L, Dahan A, Hoitsma E. Sarcoidosis and Pain Caused by Small-Fiber Neuropathy. Pain Res Treat. 2012;2012:256024. https://pubmed.ncbi.nlm.nih.gov/22952059/ 2. Culver DA, Dahan A, Bajorunas D, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52-BIO60. 3. Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2014;20(1):658-666. https://pubmed.ncbi.nlm.nih.gov/25286087/ 4. Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19(1):334-345. https://pubmed.ncbi.nlm.nih.gov/24136731/ 5. Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med. 2012;18(1):486-496. https://pubmed.ncbi.nlm.nih.gov/22183894/ 6. Swartjes M, Morariu A, Niesters M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Pain. 2014;155(11):2250-2258. 7. Zhang W, Yu G, Zhang M. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Pharmacol Res. 2016;113(Pt A):654-659. https://www.sciencedirect.com/science/article/abs/pii/S0196978116300031 8. Yao M, Watanabe M, Sun S, et al. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation. 2020;104(10):2048-2058. 9. Ahmet I, Tae HJ, Brines M, et al. Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction- dilated cardiomyopathy. J Pharmacol Exp Ther. 2013;345(3):446-456. 10. Coldewey SM, Khan AI, Kapoor A, et al. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int. 2013;84(3):482-490.